|Bid||1,460.00 x 0|
|Ask||1,468.90 x 0|
|Day's Range||1,460.00 - 1,471.70|
|52 Week Range||1,046.40 - 1,805.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||275.38|
|Earnings Date||Jul 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,238.59|
The closer you get to retirement, dividend income will rank higher among your investing objectives. Many dividend stocks won't provide all that much income each year. Investing $100,000 spread across these three dividend stocks could give you added income of close to $7,700 per year.
(Bloomberg) -- Consumer DNA testing giant 23andMe Holding Co. agreed to purchase telehealth upstart and drug-delivery service Lemonaid Health Inc. in a bid to make its personalized genetics approach part of patients’ primary care. Most Read from BloombergThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyCities' Answer to Sprawl? Go Wild.Forget Palm Springs—Santa Fe Is the New Mecca for Modern ArchitectureOne of Ca
What happened Shares of the genetic-testing company 23andMe (NASDAQ: ME) gained another 16% through Thursday's close this week, according to data from S&P Global Market Intelligence. The biotech's stock is now up by more than 34% over the past two weeks.